$BDSX

GSA Capital Partners LLP Has $365,000 Stake in Biodesix, Inc. $BDSX

GSA Capital Partners LLP significantly reduced its stake in Biodesix, Inc. (BDSX) by selling 94.8% of its shares, retaining 48,342 shares valued at $365,000. Despite this, other institutional investors like XTX Topco Ltd increased their holdings, and institutional ownership remains at 20.96%. Biodesix also reported strong quarterly results, beating EPS and revenue estimates, which contributed to a 10% stock price increase, while analysts maintain a "Moderate Buy" rating with a consensus price target of $32.50.

Original reporting
MarketBeat · MarketBeat
Published Feb 27, 2026, 10:53 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Feb 27, 2026, 12:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
GSA Capital Partners LLP Has $365,000 Stake in Biodesix, Inc. $BDSX — source image
Decision brief

The 30-second read

$BDSXBullishMed
01

Why it matters

The combination of strong earnings and institutional interest suggests a positive outlook, but the large stake reduction by GSA Capital may introduce some caution.

02

Market read

The news indicates a potentially bullish short-term trend driven by earnings and institutional activity, with some caution due to recent stake reduction.

03

What to watch

Potential market overreaction to earnings; need to assess broader industry trends and upcoming catalysts.

Timing: short to medium term (days to weeks)

Background

Biodesix, Inc. is a biotech company specializing in diagnostic solutions, with recent earnings surpassing expectations and notable institutional trading activity.

Company-level read

Ticker impact

$BDSXBullishMedium confidence
Context

The news about Biodesix, Inc. (BDSX) involves significant institutional activity and strong quarterly earnings, which are relevant for trading decisions.

Expected impact

Likely short-term upward movement with potential stabilization as market absorbs institutional changes.

Evidence & confidence

Earnings beat estimates and increased institutional interest suggest positive momentum; however, the recent large stake reduction introduces some uncertainty.

Market effects

Positive earnings and institutional interest may bolster the biotech and life sciences sectors.

Limited regional impact; primarily affecting US-based biotech stocks.

Moderate; reflects sector-specific dynamics rather than broad global trends.

Counterpoint

The significant reduction in institutional holdings could signal upcoming negative developments or profit-taking, warranting caution.

Key entities

  • Biodesix, Inc.

    A biotech firm focused on diagnostic testing and solutions.

  • GSA Capital Partners LLP

    A hedge fund that significantly reduced its stake in BDSX.

  • XTX Topco Ltd

    Increased holdings in BDSX, indicating confidence.

Related articles

$BDSXHigh

BIODESIX INC (BDSX): Results of Operations and Financial Condition

BIODESIX INC (BDSX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 bdsx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Biodesix Announces Second Quarter 2026 Results and Highlights Delivered $26.9 million in revenue, representing 34% growth in Q2 2026; Achieved 82% gross margin in Q2 2026; Maintained FY 2026 Revenue Guidance of $108-114 milli

$ACIMed

Albertsons recalls ready-to-eat items in multiple states amid salmonella-linked jalapeño investigation

Albertsons Companies said it is voluntarily recalling four ready-to-eat products containing jalapeños supplied by Taylor Farms, including items sold at Randalls in Texas. The recall followed a supplier recall tied to an ongoing federal investigation and an FDA probe of a Salmonella Javiana outbreak. FDA reported 345 illnesses in 27 states, 36 hospitalizations, no deaths.

$CMGMed

Salmonella outbreak from Mexican jalapeños reported in 27 U.S. states

U.S. health authorities are investigating a Salmonella outbreak linked to Mexican jalapeño peppers. The CDC and FDA say 345 people are ill across 27 states, with 36 hospitalizations and no deaths. The supplier, Coast Citrus Distributors, recalled peppers sent to restaurants including Chipotle and QDOBA. Chipotle removed jalapeños from some outlets and shares fell over 8% on Aug. 4.

$RKLBMedAI 8/10

Rocket Lab Just Unveiled a Game-Changing Technology Worth Watching

Rocket Lab (RKLB) said it won a $397 million U.S. Space Force contract to develop, launch, and operate multiple Flatellites for the SB-AMTI program. Flatellites are slimmer, stackable satellites intended to increase deployments per launch and integrate with Rocket Lab’s Neutron rocket. The article cites analyst forecasts for revenue rising from $602M (2025) to $1.7B (2028).